MicroRNA 130b enhances drug resistance in human ovarian cancer cells

Tumor Biology

Volumn 35, Issue 12, 2014, Pages 12151-12156

  Zong, Can ^a   Wang, Jun ^b   Shi, Tie Mei ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

Author keywords

Cisplatin; MDR1; MicroRNA 130b; Ovarian cancer cells; Paclitaxel

Indexed keywords

CISPLATIN; GLUTATHIONE TRANSFERASE; MESSENGER RNA; MICRORNA; MICRORNA 130B; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MIRN130 MICRORNA, HUMAN;

ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL VIABILITY ASSAY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; OVARIAN CANCER CELL LINE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; OVARY TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE TRANSFERASE; HUMANS; MICRORNAS; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; PACLITAXEL;

EID: 84925286093     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2520-x     Document Type: Article

References (31)

1. Mantia-Smaldone GM, Edwards RP, Vlad AM. Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies. Cancer Manag Res. 2011;13:25–38.
2. Lengyel E. Ovarian cancer development and metastasis. Am J Pathol. 2010;177(3):1053–64.
3. Jordan SJ, Cushing-Haugen KL, Wicklund KG, Doherty JA, Rossing MA. Breast-feeding and risk of epithelial ovarian cancer. Cancer Causes Control. 2012;23(6):919–27.
4. Ji K, Ye L, Mason MD, Jiang WG. The Kiss1/Kiss1R complex as a negative regulator of cell motility and cancer metastasis (review). Int J Mol Med. 2013;32(4):747–54.
5. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75:843–54.
6. Pasquinelli AE. MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. Nat Rev Genet. 2012;13:271–82.
7. Ishihara T, Seki N, Inoguchi S, Yoshino H, Tatarano S, et al. Expression of the tumor suppressive microRNA-23b/27b cluster is a good prognostic marker in clear cell renal cell carcinoma. J Urol. 2014. doi:10.1016/j.juro.2014.07.001.
8. Ma MT, He M, Wang Y, Jiao XY, Zhao L, Bai XF, et al. MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2). Cancer Lett. 2013;339(1):107–15.
9. Kenneth KWT, Zhan Z, Litman T, Bates SE. Regulation of ABCG2 expression at the 3′ untranslated region of its mRNA through modulation of transcript stability and protein translation by a putative microRNA in the S1 colon cancer cell line. Mol Cell Biol. 2008;28(17):5147–61.
10. Dai Y, Xie CH, Neis JP, Fan CY, Vural E, Spring PM. MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck. 2011;33(6):786–91.
11. Colangelo T, Fucci A, Votino C, Sabatino L, Pancione M, Laudanna C, et al. MicroRNA-130b promotes tumor development and is associated with poor prognosis in colorectal cancer. Neoplasia. 2013;15:1218–31.
12. Xia H, Qi Y, Ng SS, Chen X, Chen S, Fang M, et al. MicroRNA-15b regulates cell cycle progression by targeting cyclins in glioma cells. Biochem Biophys Res Commun. 2009;380:205–10.
13. Chen J, Feilotter HE, Paré GC, Zhang X, Pemberton JG, Garady C, et al. MicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanoma. Am J Pathol. 2010;176:2520–9.
14. Xu YY, Wu HJ, Ma HD, Xu LP, Huo Y, Yin LR. MicroRNA-503 suppresses proliferation and cell cycle progression of endometrioid endometrial cancer via negatively regulating cyclin D1. FEBS J. 2013;280(16):3768–79.
15. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009;10:704–14.
16. Farazi TA, Spitzer JI, Morozov P, Tuschl T. MiRNAs in human cancer. J Pathol. 2011;223:102–15.
17. Bueno MJ, Malumbres M. MicroRNAs and the cell cycle. Biochim Biophys Acta. 2011;12:592–601.
18. Sanchez-Diaz PC, Hsiao T-H, Chang JC, Yue D, Tan MC, Chen H-IH, et al. De-regulated microRNAs in pediatric cancer stem cells target pathways involved in cell proliferation, cell cycle and development. PLoS One. 2013;8:e61622.
19. Deng S, Calin GA, Croce CM, Coukos G, Zhang L. Mechanisms of microRNA deregulation in human cancer. Cell Cycle. 2008;7:2643–6.
20. Allegra A, Alonci A, Campo S, Penna G, Petrungaro A, Gerace D, et al. Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer (review). Int J Oncol. 2012;41:1897.
21. Sotillo E, Thomas-Tikhonenko A. Shielding the messenger (RNA): microRNA-based anticancer therapies. Pharmacol Ther. 2011;131:18–32.
22. Lai KW, Koh KX, Loh M, Tada K, Subramaniam MM, et al. MicroRNA-130b regulates the tumour suppressor RUNX3 in gastric cancer. Eur J Cancer. 2010;46(8):1456–63.
23. Wang F, Xue X, Wei J, An Y, Yao J, Cai H, et al. Hsa-miR-520h down-regulates ABCG2 in pancreatic cancer cells to inhibit migration, invasion, and side populations. Br J Cancer. 2010;103:567–74.
24. Pan YZ, Morris ME, Yu AM. MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol Pharmacol. 2009;75:1374–9.
25. Li H, Xu H, Shen H, Li H. MicroRNA-106a modulates cisplatin sensitivity by targeting PDCD4 in human ovarian cancer cells. Oncol Lett. 2014;7(1):183–8.
26. Li Z, Sha H, Wang J, Cai J, Xiao L, Lili Y, et al. MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells. Gynecol Oncol. 2010;119:125–30.
27. Andorfer P, Rotheneder H. Regulation of the MDR1 promoter by E2F1 and EAPP. FEBS Lett. 2013;587:1504–9.
28. Januchowski R, Wojtowicz K, Sujka-Kordowska P, Andrzejewska M, Zabel M. MDR gene expression analysis of six drug-resistant ovarian cancer cell lines. Biomed Res Int. 2013;241763.
29. Xing AY, Shi DB, Liu W, Chen X, Sun YL, et al. Restoration of chemosensitivity in cancer cells with MDR phenotype by deoxyribozyme, compared with ribozyme. Exp Mol Pathol. 2013;94:481–5.
30. Popęda M, Płuciennik E, Bednarek AK. Proteins in cancer multidrug resistance. Postepy Hig Med Dosw. 2014;68:616–32.
31. Beeghly A, Katsaros D, Chen H, Fracchioli S, Zhang Y, Massobrio M, et al. Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival. Gynecol Oncol. 2006;100(2):330–7.